Rajtar-Salwa, R.; Bobrowska, B.; Socha, S.; Dziewierz, A.; Siudak, Z.; Batko, J.; Bartuś, S.; Krawczyk-Ożóg, A.
Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina 2024, 60, 1124.
https://doi.org/10.3390/medicina60071124
AMA Style
Rajtar-Salwa R, Bobrowska B, Socha S, Dziewierz A, Siudak Z, Batko J, Bartuś S, Krawczyk-Ożóg A.
Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina. 2024; 60(7):1124.
https://doi.org/10.3390/medicina60071124
Chicago/Turabian Style
Rajtar-Salwa, Renata, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, and Agata Krawczyk-Ożóg.
2024. "Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk" Medicina 60, no. 7: 1124.
https://doi.org/10.3390/medicina60071124
APA Style
Rajtar-Salwa, R., Bobrowska, B., Socha, S., Dziewierz, A., Siudak, Z., Batko, J., Bartuś, S., & Krawczyk-Ożóg, A.
(2024). Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk. Medicina, 60(7), 1124.
https://doi.org/10.3390/medicina60071124